CLINICAL, NEUROLOGICAL, LABORATORY, AND PARACLINICAL FEATURES OF SPINAL MUSCULAR ATROPHY IN CHILDREN
Keywords:
Spinal muscular atrophy, children, clinical features, neurological examination, laboratory diagnostics, paraclinical methods, motor neuron disease, genetic testingAbstract
Spinal muscular atrophy (SMA) is a rare but severe genetic neuromuscular disorder characterized by the progressive degeneration of motor neurons in the spinal cord and brainstem, leading to muscle weakness and atrophy. The aim of this study is to explore the clinical-neurological, laboratory, and paraclinical characteristics of SMA in children to improve diagnostic accuracy and optimize early intervention strategies. A review of available literature and clinical case data was conducted, focusing on phenotypic presentations, genetic confirmation, and supportive diagnostic methods. Clinical-neurological findings include hypotonia, symmetrical muscle weakness, delayed motor milestones, and absent deep tendon reflexes. Laboratory diagnostics are primarily based on molecular genetic testing of the SMN1 gene, supported by electromyography and muscle biopsy when necessary. Paraclinical investigations, including neuroimaging and electrophysiological studies, provide additional insights into disease progression. Early recognition of SMA-specific features is essential for timely therapeutic decisions, particularly given the availability of disease-modifying treatments. This article highlights the significance of integrating clinical, laboratory, and paraclinical data for comprehensive management of children with SMA.
References
1. Mercuri E, Finkel RS, Muntoni F, et al. Diagnosis and management of spinal muscular atrophy: Part 1. Recommendations for diagnosis, rehabilitation, orthopedic and nutritional care. Neuromuscul Disord. 2018;28(2):103-115.
2. Finkel RS, Mercuri E, Meyer OH, et al. Diagnosis and management of spinal muscular atrophy: Part 2. Pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics. Neuromuscul Disord. 2018;28(3):197-207.
3. Kolb SJ, Kissel JT. Spinal muscular atrophy: a timely review. Arch Neurol. 2011;68(8):979-984.
4. Dangouloff T, Servais L. Nusinersen, the first approved treatment for spinal muscular atrophy: efficacy, safety, and future perspectives. Ther Adv Neurol Disord. 2019;12:175628641987831.
5. Darras BT. Spinal muscular atrophies. Pediatr Clin North Am. 2015;62(3):743-766.
6. Prior TW. Spinal muscular atrophy diagnostics. J Child Neurol. 2007;22(8):952-956.
7. Искандарова, Ш. Т., Расулова, Н. Ф., Хасанова, М. И., & Юсупалиева, К. Б. (2019). Современные проблемы гигиены почвы в условиях Узбекистана почвы в условиях Узбекистана Ташкент:" Фан.
8. Усманов, И. А., Джалилова, Г. А., & Расулова, Н. Ф. (2016). К вопросу охраны водных объектов бассейна Амударьи на примере Кашкадарьинской области. Вестник науки и образования, (2 (14)), 95-98.
9. Nazarova, S. K., Jalilova, G. A., Mukhamedova, N. S., & Rasulova, N. F. (2021). Features of distance learning organization. Annals of the Romanian Society for Cell Biology, 25(1), 339-347.
10. Расулова, Н. Ф. (2011). Ўзбекистонда педиатриянинг ривожланиш тарихи.
11. Pechmann A, Konig K, Bernert G, et al. Spinal muscular atrophy: the spectrum of disease severity in childhood. Eur J Paediatr Neurol. 2018;22(3):457-465.
12. Миррахимова, М. Х., Садуллаева, Х. А., & Кобилжонова, Ш. Р. (2022). Значение экологических факторов при бронхиальной астме у детей (Doctoral dissertation, Россия).
13. Mirrahimova, M. H., Khalmatova, B. T., & Tashmatova, G. A. (2019). Bronchial asthma in children: a modern view of the problem. Toshkent tibbiyot akademiyasi axborotnomasi, (1), 31-34.
14. Mirrakhimova, M. K. (2020). Characteristics of Allergic Pathologies Progression in Young Children. American Journal of Medicine and Medical Sciences, 10(9), 652-656.
15. Mirrakhimova, M. (2020). Improving methods of treatment of atopic pathology in children. Journal of Critical Reviews, 7(12), 190-192.
16. Саидова, Ш. А., Якубов, А. В., Зуфаров, П. С., Пулатова, Н. И., & Пулатова, Д. Б. (2024). ВЫБОР АНТАГОНИСТОВ МИНЕРАЛОКОРТИКОИДНЫХ РЕЦЕПТОРОВ ПРИ РАЗЛИЧНЫХ ПАТОЛОГИЯХ.
17. Karimov, M. M., Zufarov, P. S., Go’zal, N. S., Nargiza, P. I., & Aripdjanova, S. S. (2022). Ulinastatin in the conservative therapy of chronic pancreatitis.
18. Зуфаров, П. С., Якубов, А. В., & Салаева, Д. Т. (2009). Сравнительная оценка эффективности омепразола и пантопразола при лечении гастропатии, вызванной нестероидными противовоспалительными средствами у больных ревматоидным артритом. Лікарська справа, (3-4), 44-49.
19. Yakubov, A. V., Zufarov, P. S., Pulatova, N. I., Akbarova, D. S., Saidova, S. A., Pulatova, D. B., & Musaeva, L. J. (2022). Evaluation Of The Effectiveness Of Angiotensin-Converting Enzyme Inhibitors, Misoprostol, Omeprazole And Their Combinations On The State Of The Gastric Mucous Barrier In Indomethacin Gastropathy In Animals With Experimental Rheumatoid Arthritis. Journal of Pharmaceutical Negative Results, 13.
20. Мусаева, Л. Ж., Якубов, А. В., Зуфаров, П. С., Акбарова, Д. С., & Абдусаматова, Д. З. (2021). Клиническая фармакология лекарственных средств, влияющих на систему гемостаза.
21. Verhaart IEC, Robertson A, Wilson IJ, et al. Prevalence, incidence and carrier frequency of 5q–linked spinal muscular atrophy – a literature review. Orphanet J Rare Dis. 2017;12:124.
22. Адилбекова, Д. Б., Хатамов, А. И., Мансурова, Д. А., & Пулатов, Х. Х. (2020). Морфологическое состояние сосудисто-тканевых структур желудка у потомства в условиях хронического токсического гепатита у матери. Морфология, 157(2-3), 10-11.
23. Закиров, А. У., Пулатов, Х. Х., & Исмалов, Д. Д. (2001). Изучение противовоспалительных свойств диклозана. Экспер. и клин. фарм, (5), 50-52.
24. Пулатов, Х. Х. (2022). Влияние экспериментального сахарного диабета на надпочечники: дис. Ўзбекистон, Самарқанд.
25. Adilbekova, D. B., Usmanov, R. D., Mirsharapov, U. M., & Mansurova, D. A. (2019). MORPHOLOGICAL STATE OF EARLY POSTNATAL FORMATION OF THE ORGANS OF THE GASTROINTESTINAL TRACT AND LIVER IN OFFSPRING BORN AND RAISED BY MOTHERS WITH CHRONIC TOXIC HEPATITIS. Central Asian Journal of Medicine, 2019(4), 43-55.
26. Шералиев, И. И., & Пулатова, Х. Х. (2017). Теорема Эссена для различно распределенных случайных величин. Научное знание современности, (3), 347-349.
27. Zakirov, A. U., KhKh, P., Ismatov, D. N., & Azizov, U. M. (2001). Anti-inflammatory effect of dichlotazole. Eksperimental'naia i Klinicheskaia Farmakologiia, 64(5), 50-52.
28. De Vivo DC, Bertini E, Swoboda KJ, et al. Nusinersen initiated in infants with presymptomatic SMA. N Engl J Med. 2019;381(18):1722-1734.
29. Mendell JR, Al-Zaidy S, Shell R, et al. Single-dose gene-replacement therapy for spinal muscular atrophy. N Engl J Med. 2017;377(18):1713-1722.
30. Baranello G, Darras BT, Day JW, et al. Risdiplam in type 1 spinal muscular atrophy. N Engl J Med. 2021;384(10):915-923.
31. Glanzman AM, Mazzone E, Main M, et al. The Children’s Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND): test development and reliability. Neuromuscul Disord.
Published
Issue
Section
License
Copyright (c) 2025 Hilola Nurmatova (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
All Rights Reserved.
